Atrial fibrillation (AFib) is the most common cardiac arrhythmia (irregular heart beat) that affects millions of Americans.
AFib can lead to blood clots, stroke, heart failure and other heart-related complications. Patients with non-valvular AFib have a five times higher risk of stroke due to blood stagnating and clotting in the improperly beating part of the heart called the atrium. Twenty percent of all strokes occur in patients with AFib and AFib-related strokes are more frequently disabling or even fatal.
The most common treatment for stroke risk reduction in patients with AFib is the blood-thinner warfarin. Despite its proven efficacy, long-term warfarin therapy is not well-tolerated by some patients and also carries a significant risk for bleeding complications.
However, a new device has come to market called the WATCHMAN™ Left Atrial Appendage Closure (LAAC) device. This device is a first-of-its-kind, proven alternative to long-term warfarin therapy in patients with non-valvular atrial fibrillation. The WATCHMAN device is intended to prevent the migration of blood clots that form in the left atrial appendage (LAA) that cause stroke in AFib patients. The LAA is a thin, sack-like appendix attached to the left side of the heart and is believed to be the source of the majority of stroke-causing blood clots.
The WATCHMAN™ device offers a new, stroke-risk reduction option for patients with non-valvular AFib who are seeking an alternative to long-term warfarin therapy. The WATCHMAN™ is a catheter-delivered, minimally invasive heart implant designed to close the LAA without interfering with the left atrium, thus, reducing the risk of blood clotting and stroke for higher-risk patients. Worldwide this device has been implanted more than 10,000 times.
Cooper was the first hospital on the East Coast to implant the early-generation WATCHMAN™ device as part of a pilot study in the early 2000s. Since its FDA approval in 2015, the physicians at Cooper Heart Institute were the first in the region to perform the procedure using the newly approved device.
Cooper Heart Institute offers a variety of interventional and non-interventional treatment options for AFib that include medication as well as device options. The Structural Heart Disease Program at Cooper Heart Institute offers the WATCHMAN™ device to patients who cannot tolerate long-term warfarin therapy and have non-valvular atrial fibrillation.